774
Average capitalism enjoyer (media.mas.to)
submitted 1 year ago by yogthos@lemmy.ml to c/memes@lemmy.ml
143 comments fedilink hide all child comments
you are viewing a single comment's thread
view the rest of the comments
[-] KoboldCoterie@pawb.social 9 points 1 year ago

Insulin prices in the US is a great example of this. It's not about being competitive, it's about charging the absolute highest amount they can possibly get away with.

[-] kev@lemmy.kevhomeit.trade 1 points 1 year ago

Yes that's a great example! Capitalism is great in paper it improves quality of life and the free market make companies more competitive but big corporations abuse this and create monopolies.

[-] AchillesUltimate@lemy.lol -1 points 1 year ago

Insulin prices would be a lot lower if more people were allowed to produce and sell it.

[-] KoboldCoterie@pawb.social 4 points 1 year ago

It's not a question of not being allowed to produce it, it's anti-competitive practices by the pharmaceuticals industry, which capitalism rewards.

Specifically, drug manufacturers have repeatedly made lots of little changes to their existing insulin products in order to apply for new patents on them. This process, called “evergreening,” has discouraged competitors from developing new versions of existing insulins because they’d have to chase so many changes. This has slowed down innovation, along with “pay for delay” deals, in which insulin manufacturers pay competitors to not copy specific drugs for a period of time.

Source

Even though there are very few insulin products that have patent protection on the compound itself, the vast majority of insulin products still have patent protection on the pens and other devices that deliver the dose of insulin. Novo Nordisk has patents for Novolog, Novolin, and FIASP products; Sanofi has patents on the devices for all of its products; and Eli Lilly still has patents on some devices that deliver Humulin and Humalog.

The patent protection on the devices is significant. Because the pens and other insulin delivery devices can only be used on with one brand of insulin, competition on those products is effectively delayed. While a prospective competitor could develop a follow-on biologic or biosimilar of the insulin, it would have to develop its own delivery device.

Source

[-] AchillesUltimate@lemy.lol 1 points 1 year ago

Save for pay for delay, all of those rely on patents and copy-rights, which are government intervention.

According to the first source, it also looks like competitors are entering and offering lower prices, including open source methods (though I have no idea how that really works). One of the biggest problems for all of them is the government saying "no, you can't do this or that for whatever reason". Sometimes it's good for the government to intercede, but it seems like in this case it's helping perpetuate monopolies.

this post was submitted on 23 Aug 2023
774 points (92.6% liked)

Memes

45728 readers
940 users here now

Rules:

  1. Be civil and nice.
  2. Try not to excessively repost, as a rule of thumb, wait at least 2 months to do it if you have to.

founded 5 years ago
MODERATORS
gary_host_laptop@lemmy.ml
sexy_peach@feddit.de
cyclohexane@lemmy.ml
cypherpunks@lemmy.ml